EpiCast Report: Migraine - Epidemiology Forecast to 2023

LONDON, May 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

EpiCast Report: Migraine - Epidemiology Forecast to 2023

http://www.reportbuyer.com/pharma_healthcare/diseases/epicast_report_migraine_epidemiology_forecast_2023.html

EpiCast Report: Migraine - Epidemiology Forecast to 2023

Summary

Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following symptoms: nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal and Lipton, 2006). Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization (WHO) (Leonardi et al., 2005; Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine as the first among the neurological disorders (Leonardi and Raggi, 2013).

In 2023, GlobalData epidemiologists forecast that the total prevalent cases of migraine in the 7MM remained almost the same, with 75.83 million total prevalent cases in 2013 and 76.38 million total prevalent cases, with an annual growth rate (AGR) of 0.07% in the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of migraine, with 29.61 million total prevalent cases in 2013 and 31.13 million total prevalent cases in 2023.

GlobalData epidemiologists obtained total prevalence data for migraine from peer-reviewed journals and population-based studies in the respective markets and used consistent methodology to ensure comparability of results. Furthermore, GlobalData epidemiologists made a meaningful assumption that the age- and sex-specific total prevalence of migraine in the 7MM would remain constant throughout the forecast period because epidemiologic literature suggests relatively stable trends in the prevalence of migraine worldwide, thereby providing a realistic and meaningful forecast for the age- and sex-specific total prevalent cases of migraine in the 7MM.

Scope

- The Migraine EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of migraine in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by age (beginning at 18 years and ending at 80 years and older), sex, and the number of total prevalent cases of migraine with aura and without aura in these markets.
- The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global migraine market.
- Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for migraine therapeutics in each of the markets covered.
- Identify the number of migraine cases with aura and without aura.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.2.1 Female sex and family history are interrelated risk factors of migraine 9
3.2.2 People with migraine also suffer from several comorbidities 10
3.3 Global Trends 11
3.3.1 US 12
3.3.2 5EU 13
3.3.3 Japan 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 17
3.4.2 Sources Not Used 20
3.4.3 Forecast Assumptions and Methods 20
3.5 Epidemiological Forecast for Migraine (2013-2023) 25
3.5.1 Total Prevalent Cases of Migraine 25
3.5.2 Age-Specific Total Prevalent Cases of Migraine 26
3.5.3 Sex-Specific Total Prevalent Cases of Migraine 28
3.5.4 Age-Standardized Total Prevalence of Migraine 30
3.5.5 Total Prevalent Cases of Migraine with Aura and Migraine without Aura 32
3.6 Discussion 33
3.6.1 Conclusions on Epidemiological Trends 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 35
4 Appendix 36
4.1 Bibliography 36
4.2 About the Authors 40
4.2.1 Epidemiologists 40
4.2.2 Reviewers 40
4.2.3 Global Director of Epidemiology and Health Policy 41
4.2.4 Global Head of Healthcare 42
4.3 About GlobalData 43
4.4 About EpiCast 43
4.5 Disclaimer 43

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Migraine 9
Table 2: Prevalence of the Most Frequent Comorbidities in People with and without Migraine, Ages ?18 Years, Both Sexes 11
Table 3: One-Year Total Prevalence (%) of Migraine in the 5EU 14
Table 4: Lifetime Total Prevalence (%) of Migraine in the 3EU 14
Table 5: Criteria Proposed by the Second Edition of the International Classification of Headache Disorders (ICHD-2) 15
Table 6: Epidemiological Sources of Total Prevalence Data Used in the Analysis for Migraine and its Subtypes (Migraine with Aura and Migraine without Aura) 16
Table 7: 7MM, Total Prevalent Cases of Migraine, Ages ?18 Years, Both Sexes, N, 2013-2023 25
Table 8: 7MM, Total Prevalent Cases of Migraine, by Age, Both Sexes, N, (Row %), 2013 27
Table 9: 7MM, Total Prevalent Cases of Migraine, by Sex, Ages ?18 years, N (Row %), 2013 29
Table 10: 7MM, Total Prevalent Cases of Migraine with Aura and Migraine without Aura, Ages ?18 Years, Both Sexes, N, Row (%), 2013 32

List of Figures

Figure 1: 7MM, Total Prevalent Cases of Migraine, Ages ?18 Years, Both Sexes, N, 2013-2023 26
Figure 2: 7MM, Total Prevalent Cases of Migraine, by Age, Both Sexes, N, 2013 28
Figure 3: 7MM, Total Prevalent Cases of Migraine, by Sex, Ages ?18 Years, N, 2013 30
Figure 4: 7MM, Age-Standardized Total Prevalence of Migraine, Ages ?18 Years, 2013 31
Figure 5: 7MM, Total Prevalent Cases of Migraine with Aura and Migraine without Aura, Ages ?18 Years, Both Sexes, N, Row (%), 2013 33

Read the full report:
EpiCast Report: Migraine - Epidemiology Forecast to 2023

http://www.reportbuyer.com/pharma_healthcare/diseases/epicast_report_migraine_epidemiology_forecast_2023.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer